Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors

This is a Phase 2, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Belvarafenib in patients with BRAF-altered primary brain tumors (Cohort 1) and metastatic brain tumors (Cohort 2). Eligible patients are those with a confirmed BRAF alteration identified by next-generation sequencing (NGS). Patients who meet the eligibility criteria will receive a detailed explanation of the study, including its purpose, procedures, potential benefits, and risks. Only patients who voluntarily provide written informed consent will be enrolled. All enrolled patients will re

Trial Details

NCT ID
NCT07688356
Phase
PHASE2
Sponsor
Samsung Medical Center
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Belvarafenib
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Male or female patients aged 19 years or older.
  • Histologically confirmed primary brain tumor or metastatic brain tumor.
  • Documented BRAF mutation, including point mutations (e.g., V600E) or BRAF fusion mutations.
  • Willing and able to provide written informed consent prior to participation in the study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →